

5th International Symposium on Kallikreins and Kallikrein-Related Peptidases

Biochemistry, Molecular Biology, and Association to Disease



Conference Program and Proceedings

**September 28 – October 1, 2013
Toronto, Canada**

Hosted by the Li Ka Shing Knowledge Institute, St. Michael's Hospital

Mavridis, Konstantinos

MicroRNA 224: a KLK-targeting miRNA with deregulated expression and promising prognostic value in prostate cancer

K. Mavridis¹, K. Stravodimos², A. Scorilas¹.

¹Department of Biochemistry and Molecular Biology, University of Athens, Panepistimiopolis, 15701, Athens, Greece, ²First Urology Department, Medical School, University of Athens, "Laiko" General Hospital, 17 Ag Thoma St., 11527, Athens, Greece.

Hsa-miR-224-5p (miR-224) is a tumor-related miRNA, which targets the expression of several Kallikrein (KLK) genes. The present study aims to analyze miR-224 expression in prostate cancer (CaP) cancer and to evaluate its prognostic significance. Snap - frozen tissue samples were obtained from a well-characterized cohort of CaP and benign prostatic hyperplasia (BPH) patients. MiR-224 expression levels were measured using qPCR after the isolation, polyadenylation and reverse transcription of total RNA via a poly(T) adapter. MiR-224 was found to be downregulated in CaP compared to BPH patients ($p < 0.001$). The expression levels of miR-224 were also gradually decreased in advanced pathological stage and high Gleason score CaP tumors (all p values < 0.05). MiR-224 expression was associated with improved biochemical progression-free survival of CaP patients (HR=0.314, $p = 0.013$). Our data reveal that the kallikrein-targeting miR-224 can be viewed as a potential prognostic biomarker for prostate cancer patients.

Acknowledgements: This research has been co - financed by the European Union (European Social Fund - ESF) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) - Research Funding Program: THALES. Investing in knowledge society through the European Social Fund. (UoA -BIOPROMO, MIS 377046).

Meinander, Kristian

Hydrocarbon isosteres of disulfide bridges in peptides that stimulate the proteolytic activity of KLK3

Kristian Meinander,^a Janne Weisell,^b Miiikka Pakkala,^b Roope Kallionpää,^a Can Hekim,^c Ulf-Håkan Stenman,^c Hannu Koistinen,^c Jouko Vepsäläinen,^b Ale Närvänen,^b Kristina Luthman^d and Erik A.A. Wallén^a

^aDivision of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Helsinki, Finland; ^bSchool of Pharmacy, University of Eastern Finland, Kuopio, Finland; ^cDepartment of Clinical Chemistry, University of Helsinki, Finland; ^dMedicinal Chemistry, Department of Chemistry and Molecular Biology, University of Gothenburg, Sweden.

Stimulation of the enzymatic activity of kallikrein-related peptidase 3 (KLK3, also known as prostate specific antigen, PSA) may be beneficial for patients with prostate cancer due to the antiangiogenic activity of KLK3. So far, only a few peptides have been reported to stimulate KLK3. The most potent ones are denoted C4 and B2, both of which increase the proteolytic activity of KLK3 several-fold at micromolar concentrations. However, no small molecule compounds with comparable activity have been reported. The *in vivo* use of natural peptides is highly challenging. With this in mind we set out to construct synthetic protocols for replacing both internal and terminal disulfide bridges with more stable hydrocarbon isosteres. We have synthesized several pseudopeptide analogs based on both the C4 and B2 peptides. All of these pseudopeptides show a significant stimulating effect on KLK3, the most potent ones showing a more than two-fold activation at a concentration of 20 $\mu\text{g/ml}$ (13-14 μM).

Scorilas, Andreas

*1- Downregulation of the *KLK2*- & *KLK4*-targeting *miR-378a* predicts the short-term relapse of prostate cancer patients*

M. Avgeris¹, K. Mavridis¹, K. Stravodimos², A. Scorilas¹

¹Department of Biochemistry and Molecular Biology, University of Athens, Panepistimiopolis, 15701, Athens, Greece, ²First Urology Department, Medical School, University of Athens, "Laiko" General Hospital, 17 Ag Thoma St., 11527, Athens, Greece.

The deregulation of several miRNAs in prostate cancer (PCa) provides a novel pool of candidate tumor markers. Using *in silico* approaches, we have identified hsa-miR-378a-3p (miR-378a) as a potential post-transcriptional regulator of *KLK2* and *KLK4*. The aim of the study is the evaluation of the clinical significance of miR-378a for the prediction of PCa patients' outcome. Prostate tissue specimens obtained from 73 PCa and 64 BPH patients. Following extraction, total RNA was polyadenylated and reverse transcribed using a poly(T) adapter. A SYBR-Green based qPCR assay was applied thereafter for the quantification of miR-378a levels. Although miR-378a levels were not significantly altered between PCa and BPH, a statistically strong downregulation of miR-378a was observed in higher Gleason score ($p=0.018$) and larger diameter ($r_s=-0.402$; $p=0.034$) tumors, as well as in patients with elevated PSA serum levels ($r_s=-0.365$; $p<0.001$). Moreover, Kaplan-Meier survival curves pointed out the significantly shorter disease-free survival (DFS) of the PCa patients with reduced miR-378a levels ($p=0.034$). Finally, in high-recurrence risk patients, the reduced miR-378a levels revealed to be an independent predictor of poor DFS ($p=0.030$). Our data highlight that miR-378a loss increases the risk for short-term relapse of the PCa patients.

Acknowledgements: This research has been co - financed by the European Union (European Social Fund - ESF) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) - Research Funding Program: THALES. Investing in knowledge society through the European Social Fund. (UoA -BIOPROMO, MIS 377046).

*2- *KLK8* mRNA expression analysis in breast cancer: downregulation in cancerous tissues and in metastatic disease*

K. Michaelidou¹, A. Kladi-Skandalis¹, C. Haritos³, S. Stamatopoulou², I. Misitzis³, A. Ardavanis² and A. Scorilas¹

¹Department of Biochemistry and Molecular Biology, University of Athens, Greece; ²First Department of Medical Oncology and ³The Breast Clinic, "Saint Savvas", Anticancer Hospital, Athens, Greece.

KLK8, like other members of the *KLK* family, may prove to be a promising clinical tool for breast cancer (BC). The objective of this study was the quantification of *KLK8* mRNA expression in BC tissues, and the initial determination of its clinical utility as a potential BC biomarker. Therefore, total RNA was isolated from 50 breast tumors and their matched normal adjacent tissues, cDNA was prepared and *KLK8* mRNA expression analysis was performed by comparative Ct method. The mRNA levels of *KLK8* were found to be significantly downregulated in BC specimens compared to non-cancerous counterparts ($p=0.002$). Furthermore, patients with metastatic BC showed significantly lower *KLK8* expression compared to those with organ confined tumors ($p=0.031$). Moreover, *KLK8* mRNA levels were found to be significantly increased in HER2-positive compared to HER2-negative BC ($p=0.017$). Additionally, a negative correlation was observed between *KLK8* and PgR expression levels ($r_s=-0.352$; $p=0.048$). On the contrary, no significant relationship was observed between *KLK8* mRNA levels and histological tumor grade, TNM stage, or ER status. Nevertheless, our preliminary analysis, which will be extended in a larger patients' cohort, proposes a possible tumor suppressor role of *KLK8* in BC and demonstrate its biomarker potential for this malignancy.